Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779113 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
A Phase 1 study, sponsored by Hutchmed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT03779113 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 69 participants.
The verdict
NCT03779113, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
Interventions
- DRUG HMPL-523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2025-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03779113
The ClinicalTrials.gov registry entry for NCT03779113 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HMPL-523 is the first listed.
NCT03779113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03779113 about?
NCT03779113 is a clinical study titled "An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma". This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
What is the current status of trial NCT03779113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2019-09-26. Estimated completion is 2025-02-26.
What interventions are being tested in trial NCT03779113?
The interventions under investigation include: HMPL-523 (DRUG).
Who is sponsoring clinical trial NCT03779113?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.